SCHEMBL6489898

SCHEMBL6489898

O=Cc1ccc2c(c1)ncn2C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.42
NPC1 O15118 2/20 0.39
HPGD P15428 2/20 0.39
RAB9A P51151 1/20 0.39
HDAC1 Q13547 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
ALDH1A1 P00352 4/20 0.36
CYP2A6 P11509 1/20 0.36
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3044076 0.91 KDR (0.40) FGFR1NPC1HPGDRAB9AHDAC1
SCHEMBL6489900 0.89 FGFR1 (0.45) FGFR1NPC1ALDH1A1CYP2A6KDM4E
SCHEMBL3050820 0.87 FGFR1 (0.42) FGFR1NPC1HPGDRAB9AALDH1A1
SCHEMBL3038570 0.82 FGFR1 (0.39) FGFR1NPC1ALDH1A1CYP2A6KDM4E
SCHEMBL3047005 0.80 ALDH1A1 (0.35) FGFR1NPC1HPGDRAB9AALDH1A1
SCHEMBL3046969 0.80 DRD1 (0.35) FGFR1
SCHEMBL3044219 0.80 DRD1 (0.35) FGFR1
SCHEMBL3050411 0.80 FGFR1 (0.33) FGFR1TP53MAPTTHRB
SCHEMBL3039306 0.79 FGFR1 (0.45) FGFR1NPC1ALDH1A1CYP2A6KDM4E
SCHEMBL3048493 0.79 AKR1C3 (0.41) FGFR1ALDH1A1KDM4EPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861530-B2 Piperidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-03-01 US disclosed
US-6492392-B1 INHIBITING TUMOR CELL PROLIFERATION KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-12-10 US disclosed
US-20020137770-A1 Piperidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-26 US disclosed
WO-2001085716-A1 2-PIPERIDONE COMPOUNDS FOR THE TREATMENT OF CANCER KYOWA HAKKO KOGYO CO., LTD (JP) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137770-A1 Piperidine derivatives CIP2A, PARP2, TP53 FGFR1 4100/4885NPC1 1427/4885HPGD 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.